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Vascular cell adhesion molecule-I (VCAM-1) expression in murine
lupus nephritis. Vascular cell adhesion molecule-i (VCAM-1) is a cell
surface protein which mediates adherence of inflammatory cells to
target cells by binding with the f31-integrin ligand Very Late Antigen-4
(VLA-4) on leukocytes. The expression of VCAM- 1 was investigated in
a murine model of lupus nephritis, the autoimmune MRL/lpr mouse.
Compared with normal mice, MRL/lpr kidneys show increased
VCAM-1 expression not only in the endothelium, but also in cortical
tubules and glomeruli. Increased steady-state VCAM-l mRNA levels
(—3 kB) are detected in the kidney of nephritic MRL/lpr mice. Two
additional transcripts (—-2 and —1.8 kB) are present in autoimmune
MRL/lpr but not in normal mice. Like ICAM-l, VCAM-l is also
upregulated in vitro in renal cortical tubular and mesangial cells by
TNF-a, IL-I and IFN-y. T cell and macrophage cell lines adhere to
TNF-a stimulated tubular epithelial cells by using the VCAM-l/VLA-4
and the ICAM-l/LFA-l binding pairs. Kidney tissue sections from
nephritic MRL/lpr also display increased adhesiveness for T cell and
macrophage cell lines, and for MRLIIpr lymph node cells when com-
pared with normal kidney sections. This enhanced adhesiveness of
MRL/lpr kidney tissue is inhibited with monoclonal antibodies targeting
the VCAM-l and ICAM-1 molecules. Thus, VCAM-1 and ICAM-1
function as renal parenchymal adhesion molecules and mediate the
adherence of pathogenic inflammatory cells in murine lupus nephritis.
Vascular cell adhesion molecule-i (VCAM-l) is one of sev-
eral cell surface glycoproteins mediating the binding of leuko-
cytes to cytokine-stimulated endothelium [1—3]. A member of
the immunoglobulin supergene family, VCAM-1 binds with the
leukocyte 1-integrin, Very Late Antigen-4 (VLA-4), at a site
distinct from the fibronectin binding site [4]. VCAM-l is an
inducible cell adhesion molecule and its expression is upregu-
lated by tumor necrosis factor-a (TNF-a) and interleukin-l
(IL-i) in human endothelial cells [1, 5]. Thus, VCAM-1 is
mainly expressed by cytokine-activated endothelium, with little
or none detectable in normal human vessels [6].
VCAM-l, together with ICAM-1, ICAM-2 and ELAM-1,
plays an important role in endothelial adhesion and transmigra-
tion of leukocytes, thus localizing immune cells at a site of
inflammation [2, 7, 8]. Recent studies in human tissues have
shown that VCAM-l also has a nonvascular distribution, sug-
gesting that other cell types bind leukocytes by using the
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VCAM-l/VLA-4 adhesive pair. Thus, VCAM-l can be detected
in bone marrow stromal cells [9], lymphoid dendritic cells [10],
tissue macrophages, synovium [11], and focally on renal tubular
epithelium [6]. Some of these VCAM-l positive parenchymal
cells, for example bone marrow stromal cells, have already
been shown to interact with immune cells through the ligand
VLA-4 [8, 12].
The expression of VCAM-1 and the pathogenetic role of
VCAM-1/VLA-4 interactions in autoimmunity has not been
investigated. Using the autoimmune MRL/lpr model of murine
lupus nephritis, we found that VCAM-1 is upregulated not only
in endothelial cells in MRL/lpr kidney, but also in renal tubular
epithelial cells and glomeruli. Furthermore, MRLIIpr kidney
sections display increased adhesiveness for T cells and macro-
phages. This enhanced adhesiveness can be blocked with MAb
targeting the ICAM-1 and VCAM-1 molecule. Thus, enhanced
VCAM-l and ICAM-1 expression confers increased adhesive-
ness to the renal parenchyma in MRL/lpr lupus nephritis, and
serves as a pathway by which inflammatory cells adhere to the
renal tissue to promote renal injury.
Methods
Mice
Normal female BALB/c and C3H/FeJ mice were from Jack-
son Laboratories (Bar Harbor, Maine, USA). Autoimmune
MRL/MpJ-lpr/lpr and congenic MRL/MpJ— +1+ were from the
local colony of the University of Alabama at Birmingham,
Alabama, USA. Mice were maintained on standard laboratory
chow.
Materials
Tissue culture reagents were from Gibco (Grand Island, New
York, USA), and chemicals from Sigma (St. Louis, Missouri,
USA). The rat monoclonal antibody (MAb) M/K-2.7 (IgG1)
directed against murine VCAM-1 [9] was provided by Dr. Paul
W. Kincade (Oklahoma City, Oklahoma, USA). The rat IgG,
MAb Rl-2 (anti-murine VLA-4a) [13] was provided by Dr.
Irving L. Weissman (Stanford, California, USA). The irrelevant
rat IgG2 MAb B 1 ES (anti-human fibronectin receptor) [14] was
given by Dr. Caroline Damsky (San Francisco, California,
USA). The hybridomas producing the rat IgG2 MAb YN1/l.7.4
(anti-ICAM-1) [15], IgG2 MAb M17/4.2 (anti-LFA-la) [16] and
the anti-Fcy receptor MAb 2.4G2 1117] were from the American
Type Culture Collection (ATCC, Rockville, Maryland, USA).
903
904 Wuihrich: VCAM-I in murine lupus nephritis
Recombinant murin TNF-a and IFN-y were provided by
Genetech Inc. (South San Francisco, California, USA), and
rmulL-l was donated by Hoffmann-La Roche (Nutley, New
Jersey, USA). Recombinant murine IL-4 was a gift from
Sterling Drug Inc. (Malvern, Pennsylvania, USA), and rmulL-6
was given by Genetics Institute (Cambridge, Massachusetts,
USA). Recombinant human IL-8 was from Pepro Tech Inc.
(Rocky Hill, New Jersey, USA). A 2 kB cDNA (Nor! fragment)
encoding two-thirds of the murine VCAM-l gene [181 was
provided by Dr. Roy Lobb, Biogen Inc. (Cambridge, Massa-
chusetts, USA).
Primary cultures of mouse cortical tubular cells and mesan-
gial cells were established as described [19—211. Tubular epithe-
ha! cells (TEC) were grown to confluence in collagen-coated (10
g/ml) tissue culture dishes in modified Ki media [1:1 mixture
of Dulbecco's modified Eagle's medium (DMEM) and Ham's
Fl2, containing in addition 5% fetal calf serum, 25 m Hepes,
100 U/mi penicillin, 100 pg/ml streptomycin, 5 g/m1 insulin, 5
g/ml transferrin, 1 ngfml prostaglandin E1, 5 x 10 11M triiodo-
thyronine, 108M sodium selenite, S x 108M hydrocortisone,
and 20 ng/mi EGFJ. Mesangial cells (MC) were grown in RPM!
1640 supplemented with 10% FCS, 10 mrvi Hepes, 100 U/mi
penicillin and 100 g/ml streptomycin. TEC were used in
experiments between passage 0 and 1, and MC between passage
3 and 6.
SV4O transformed TEC derived from C3H/FeJ mice (Cl
cells) were grown in modified Ki media as described [19]. The
SV4O transformed mouse cortical tubule (MCT) cell line (pro-
vided by Dr. T. Haverty) was grown in RPM! 1640 with 10%
FCS [22]. The murine T hybrid cell lines 3A9 [23] and ClO [24]
were provided by Dr. Paul M. Alien (St. Louis, Missouri,
USA), and Dr. Laurie H. Glimcher (Boston, Massachusetts,
USA), respectively. The murine monocytic cell lines P388D1
(CCL 46) and IC-21 (TIB 186) were obtained from ATCC.
These T and monocytic cell lines were cultured in RPM! 1640
with 10% FCS, containing 10 mM Hepes and antibiotics.
Immunoperoxidase staining of kidney sections
Slices of murine kidneys (MRL/lpr, MRL/+ +, BALB/c and
C3H/FeJ) were snap frozen in liquid nitrogen, cut on a cryostat
at 6 m and stained as previously described [25, 26]. Briefly,
sections were transferred to gelatin-coated slides, fixed in
acetone, and then blocked with 5% horse serum in 50 mrvi Tris
buffer (pH 7.6). Sections were then incubated with diluted MAb
for two hours at room temperature in a moist chamber, washed
in Tris buffer, and incubated for 90 minutes with horseradish-
peroxidase conjugated goat anti-rat Ig (1:75; Southern Biotech-
nology, Birmingham, Alabama, USA). After washing, the sec-
tions were developed with 3,3 '-diaminobenzidine (0.5 mg/mi) in
Tris buffer containing 0.015% H202. Sections were then rinsed
and counterstained with methyl-green/alcian blue. Controls
included omission of the primary antibody, and staining with
irrelevant antibodies.
RNA extraction and Northern analysis
Total RNA from kidney cortex was isolated using lysis in
guanidinium isothiocyanate (GITC), and centrifugation at
35,000 rpm through a CsCl2 gradient overnight as described
[25—27]. Total RNA was also isolated from monolayers of
primary cultures of TEC or from transformed TEC by a
single-step extraction method as previously described [19, 28],
using 4 M GITC, 0.5% sarcosyl, 0.1 M /3-mercaptoethanol in 25
m sodium citrate (pH 4.2) to lyse the cells. After phenol and
chloroform extraction, RNA from cultured cells was precip-
itated twice with isopropanol, and washed with 75% ethanol.
All RNA samples were quantitated, and 25 g aliquots of total
RNA were then denatured with 1 M glyoxal and 50% DMSO,
and electrophoresed through a 1.5% agarose gel. The RNA was
then transferred onto GeneScreen nylon membranes (New
England Nuclear, Boston, Massachusetts, USA). The mem-
branes were baked at 80°C for two hours and prehybridized
with 25 g/ml yeast tRNA and 25 .tg/ml salmon sperm DNA.
Probes were radiolabeled by primer extension using random
hexanucieotides [29]. Blots were hybridized overnight at 42°C
in 50% formamide, 5 x SSC, lx Denhardt's and 1% SDS. Blots
were then washed under stringent conditions (final wash in 0.1
x SSC, 1% SDS, 65°C). Following hybridization the blots were
exposed to Kodak X-AR film. All blots were also rehybridized
with a murine /3-actin probe to ensure that equal amounts of
RNA were loaded for electrophoresis.
Cell ELISA
VCAM-1 expression by cultured renal tubular and mesangiai
cells was analyzed using a cell ELISA. After stimulation, cells
were trypsinized lightly and washed once with phosphate-
buffered saline (PBS) containing 5% FCS, and were then
incubated with primary antibody M/K-2.7 culture supernatant
at 1:20 for one hour at 4°C. Controls included incubation with
irrelevant MAb or omission of primary antibody. Cells were
then washed twice and incubated with horseradish-peroxidase-
conjugated goat anti-rat Ig at 1:400 in PBS/5% FCS for one hour
at 4°C. Cells were washed again, and the pellet was resus-
pended in 0.1 M phosphate-citrate buffer (pH 5.0) containing 50
g/ml of the substrate o-phenylenediamine dihydrochioride and
0.004% H202. After eight minutes, 20% vol/vol of concentrated
sulfuric acid was added to stop the reaction. Supernatants were
then transferred to 96-well plates, and the optical density (OD)
was read at 490 nm on a Thermo Max microplate reader
(Molecular Devices, Menlo Park, California, USA). Delta OD
were calculated by subtracting the OD of cells incubated
without primary antibody or irrelevant antibody from cells
incubated with anti-VCAM-l MAb MIK-2.7. Means SE were
then calculated (N = 3).
Flow cyto?netry
Tubular epithelial cells were trypsinized lightly, washed once
with PBS/5% FCS, and incubated with diluted (1:20) primary
antibody culture supernatant for one hour at 4°C. Cells were
washed twice, and incubated with FITC-conjugated affinity
purified goat anti-rat IgG F(ab')2 fragment (Cappel, Cochran-
yule, Pennsylvania, USA) for one hour at 4°C. Cells were
washed twice, and fixed with 1% paraformaldehyde in PBS.
Cells were then analyzed on a Becton-Dickinson flow cytome-
ter.
Immunoprecipitation
Unstimulated and stimulated TEC were surface labeled by a
sulfo-succinimidobiotin procedure, according to Miyake Ct al
[91. Cells were trypsinized and washed three times with HBSS
(pH 8.0). Cells (1 x l0) were then resuspended in I ml of 0.9%
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saline containing 0.1 M Hepes (pH 8.0). Sulfo-NHS-biotin
(Pierce Chemical Co., Rockford, Illinois, USA) was added to a
final concentration of 0.1 mg/ml. After a 40 minute incubation,
the cells were washed three times with RPMI 1640, and cell
lysates were prepared at 4°C in 400 1d of lysis buffer containing
1% NP-40, 50mM iodoacetamide, 50 m Tris-HC1 (pH 8.0), 150
mM NaCI, 5 mri EDTA in the presence of protease inhibitors
(PMSF 1 g/ml, soybean trypsin inhibitor 10 g/ml, leupeptin
10 g/ml, aprotinin 0.3 U/mI). The lysates were then precleared
twice with 50 d of goat anti-rat IgG Sepharose 4B conjugated
with normal rat IgG (Zymed Laboratories, South San Fran-
cisco, California, USA). Immunoprecipitation was then carried
out with anti-murine VCAM-1 MAb M/K-2.7 conjugated with
anti-rat IgG Sepharose 4B at 4°C for one hour. After three
washes with a buffer containing 50 mivi Tris-HC1 (pH 8.3), 0.6 M
NaC1, 0.5% NP-40, and 0.1% sodium azide, the bound proteins
were released by boiling for five minutes in sample buffer.
SDS-PAGE using a 7.5% gel was then carried out using a
Bio-Rad minigel apparatus (Bio-Rad, Richmond, California,
USA) under reducing conditions. Proteins were then electro-
phoretically blotted onto nitrocellulose. The membranes were
blocked for one hour at room temperature in PBS containing 2%
BSA and 0.05% Tween 20. The membranes were then incu-
bated for one hour with 0.1% horseradish peroxidase-conju-
gated avidin (Bio-Rad). After two washes with PBS containing
0.05% Tween 20, biotinylated proteins were visualized with
PBS containing 0.6 mg/mI 4-chloro-1-naphtol, 0.003% hydrogen
peroxide, and 20% methanol.
Adherence assays
Tubular epithelial cells (Cl) were grown to confluence in
96-well plates, and were then stimulated with TNF-a (10 to 100
nglml) IFN-y (100 U/mI) for 18 hours to induce adhesion
molecules. Cells were washed once before use. The murine T
and monocytic cell lines 3A9, ClO, P388D1 and IC-21 (5 x 106
cells) were radiolabeled for two hours with 50 Ci Na5 'Cr04 in
300 p1 of RPMI 1640 medium containing 25% FCS. Labeled
cells were washed three times with RPMI 1640. Cells (l0
cells/well) were then layered onto TEC. Antibodies were added
at the same time (supernatants 1:20; purified MAb 10 .tg/ml).
After a 90 minute incubation at 37°C, nonadherent cells were
removed by gently washing the wells with equal force, using 200
p1 aliquots of warmed medium for a total of three washes. The
cells were then lysed with 0.1 N NaOH, and 100 p1 aliquots of
supernatant were counted in a y-counter (Beckman Instruments
Inc., Fullerton, California, USA). All experimental conditions
were performed in triplicate; SE was below 10%. All experimen-
tal protocols were performed at least three times.
Adherence to kidney sections
Normal and autoimmune kidney sections were used to deter-
mine the contribution of VCAM-l and ICAM-1 to the adhesive-
ness for leukocytes in these tissues. ClO T cells, IC-2l macro-
phages and unfractionated MRL/lpr lymph node cells were
harvested and resuspended at iO cells/ml. Thick cryostat
sections (20 tim) from C3H/FeJ, MRL/+ + and MRL/lpr kid-
neys were placed onto gelatin-coated glass slides, dried at 37°C,
and were washed once with RPMI 1640 containing 10% FCS.
Cells (2 x 106) were then layered onto these kidney sections,
and were adhered for 20 minutes at room temperature, in the
presence or absence of inhibitory MAb. Nonadherent cells
were removed by gently washing the sections five times with
200 p1 media. Adherent cells were then counted in eight
separate high power fields using a microscopic grid. All the
experimental protocols were performed at least three times.
Results
VCAM-1 and VLA-4 expression in a murine model of lupus
nephritis
We studied normal kidneys and kidneys from autoimmune
MRL/lpr mice with nephritis by immunoperoxidase for
VCAM-1 and VLA-4 expression, using the monoclonal antibod-
ies M/K-2.7 and Rl-2, respectively (Fig. 1, Table 1). VCAM-1 is
constitutively expressed in endothelium of large vessels, and in
peritubular capillaries of normal BALB/c and C3H/FeJ mice
(Fig. lA). Similar results are obtained with congenic MRL/+ +
which lack the lpr gene. A significant increase in VCAM-1
expression is detected in endothelial cells and in the glomerular
mesangium of autoimmune MRL/lpr with nephritis (Figs. 1B,
lC). Furthermore, a striking upregulation of VCAM-1 is de-
tected in renal cortical tubules (Figs. 1D, 1E). The distribution
in cortical tubules is focal in mice with less severe renal disease,
but becomes more diffuse in mice with severe renal injury.
Medullary tubules do not express VCAM-l. A correlation
between severity of disease (measured by degree of proteinuria
and histopathological score) and VCAM-l expression is de-
tected (Table 1). Tubular VCAM-l expression is particularly
strong in areas of infiltrating cells (Fig. 1F).
VLA-4 can be detected at low levels in glomeruli of normal
mice. Autoimmune MRL/lpr have increased numbers of VLA-4
positive cells in glomeruli (Figs. 1G, lH). VLA-4 positive
inflammatory cells are also detected in the interstitium of
autoimmune MRL/lpr but not of normal mice. Staining is also
seen in perivascular infiltrates of MRL/lpr mice (Fig. 10).
To examine VCAM- 1 expression at a transcriptional level,
we extracted RNA from kidneys of normal and autoimmune
mice. Northern analysis demonstrates that steady-state mRNA
levels (—3 kB in size) can be detected in the kidney of normal
mice (Fig. 2A). In MRL/lpr mice a striking increase in mRNA
levels can be detected, correlating with the enhanced VCAM-l
protein expression seen by immunoperoxidase. Furthermore,
two additional transcripts are detected in autoimmune mice, but
not in normal mice (——2 and — 1.8 kB in size). Rehybridization
with the murine -actin probe confirmed that equal amounts of
RNA were present in all lanes (Fig. 2B).
Tubular epithelial and mesangial VCAM-1 surface expression
is upregulated by cytokines
We and others have previously shown that renal tubular
epithelial [26] and mesangial cells [21] in culture express
ICAM-l. ICAM-1 is upregulated in these cells by the cytokines
IFN-y, TNF-a and IL-i. Figure 3 demonstrates that the adhe-
sion molecule VCAM-1 is also expressed in primary cultures of
mouse cortical tubular and mesangial cells. Upon stimulation
with TNF-a (20 ng/ml), IL-i (20 nglml) or IFN-y (100 U/ml),
upregulation of VCAM-l expression is seen in both cell types.
A further stimulation is evident when IFN--y and TNF-a are
combined. Similar results were obtained with the previously
characterized SV4O transformed mouse renal tubular epithelial
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Table 1. VCAM-1 expression in normal and autoimmune kidneys
Strain
Age
month N Ua(0—4)
Histology"
(0—4)
VCAM- I expression'
Cortical
tubules Glomeruli Endothelium
BALB/c
C3H/FeJ
MRL/++
MRL/lpr
3—5
2—4
4—7
3—4
4—5
5—6
>6
3
3
5
2
6
4
2
0—!
0—1
0-1
2—3
1—3
1—3
2—4
0
0
1
2—3
2—4
3—4
3—4
Q—1
0—1
0-1
2
1—3
2—3
3
0—1
0—1
0—1
1
1
1—2
2—3
1—2
1—2
1-2
2
2
2—3
2—3
Kidneys from normal and autoimmune mice were snap frozen, cut (6 jsm) and stained by indirect immunoperoxidase, using anti-VCAM-1 MAb
M/K-2.7.
a u denotes urinary proteins, quantitated from 0 to 4 by dipstick.b A previously described histopathological score ranging from 0 to 4 was used as described [19, 261 to assess the degree of renal injury (0, normal;
1, small increase of cells within mesangium; 2, more pronounced mesangial proliferation and perivascular infiltration in cortex and medulla; 3,
lobular formation of glomerulus, and prominent perivascular mononuclear infiltration; 4, glomerular crescent formation, presence of sclerotic
glomeruli, tubular atrophy, casts and vasculitis).
VCAM-1 expression was scored on a scale from 0 to 3: 0, not detectable; 1, weak; 2, moderate; 3, strong staining. Ranges from 2 to 6
animals/group are reported.
Fig. 2. Northern blot analysis of total RNA from kidney cortices, hybridized with muVCAM-1 (A) and rehybridized with 13-actin (B) cDNA. Normal
mice (3.5-month-old BALB/c, 2-month-old C3H/FeJ; lanes I and 2) and congenic MRL/+ + (4-, 7-and 7-month-old; lanes 3 to 5) have low VCAM-1
mRNA levels at 3.0 kB. Nephritic MRL//pr (3-, 4-, 5-, 5.5- and 6-month-old, lanes 6 to 10) have increased VCAM-l mRNA steady-state levels at
3.0 kB, and display additional transcripts. Exposure time for VCAM-l was 5 days.
cells lines Cl and MCT. As in primary cultures of cortical
tubular cells, the cytokines TNF-a, IL-i and IFN-y stimulate
VCAM-i cell surface expression in these cell lines. Other
stimuli, including IL-4, IL-6 and IL-8 are without effect on
VCAM-l expression (not shown). Figure 4 shows a flow cyto-
metric analysis and demonstrates that VCAM-l is constitu-
tively expressed by these cells. Upregulation occurs with
TNF-a/IFN-y stimulation, as indicated by a shift in the fluores-
cence to the right. The range of fluorescence in these cells is
broad, spanning 2 to 2.5 logs, indicating a large difference in the
amount of VCAM- I expressed by individual cells.
Figure 5A shows the dose-response curve of VCAM-1
Fig. 1. Immunoperoxidase staining of kidney for VCAM-1 and VLA-4a. A. Kidney from 4-month-old MRL/+ + stained for VCAM-l (peritubular
capillaries are positive). B. Kidney from 4-month-old proteinuric MRL/Ipr demonstrating intense VCAM-I staining in vascular endothelium. C.
Kidney from 4-month-old proteinuric MRL/lpr, demonstrating strong glomerular VCAM-1 expression. D. Focally positive tubules in 4-month-old
proteinuric MRL/lpr. E. Tubular and glomerular VCAM-l expression in 4-month-old MRL//pr. F. Enhanced tubular staining in area of
inflammatory infiltrate (5-month-old MRL/lpr). G. Kidney from 5-month-old proteinuric MRL/lpr stained with anti-VLA-4a MAb; positive staining
in glomeruli and perivascular infiltrate is detected. H. Strong VLA-4 positive staining in 4-month-old MRL/lpr glomeruli. Reproduction of this
figure in color was made possible by a grant from Sandoz Pharmaceuticals Corporation, East Hannover, New Jersey, USA.
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Fig. 3. VCAM-l expression by BALB/c cortical tubular epithelial cells
(TEC; A) and mesangial cells (MC; B) in response to 18 hours of
stimulation with TNF-a (20 ng/ml), IL-I (50 and 20 ng/ml), IFN-y (200
and 100 U/mi) and TNF-a plus IFN-y. Cells were stained in a cell
ELISA with anti-VCAM-1 MAb M/K-2.7. Results are expressed as
increase of OD at 490 nm above background (mean SE; N = 3).
VCAM-1 is constitutively expressed, and up-regulated by TNF-a, IL-i
and IFN-y. Synergy occurs when TNF-a and IFN-y are combined.
Figure is representative of 1 out of 3 experiments.
expression in Cl cells for TNF-a. Induction of VCAM-l is
apparent at ito 10 nglml, and reaches a maximum at 100 ng/ml.
Dose-response curves for IL-i reveal that stimulation is dose-
dependent between 100 pg/mI and 10 ng/mI, and for IFN-y
between 5 and 500 U/mi (not shown). Figure 5B shows that
VCAM- 1 is induced half-maximally after three hours in re-
sponse to 100 ng/ml TNF-a, and that maximal expression
occurs after 6 hours. VCAM-1 expression then declines
slightly, but remains sustained at least for 48 hours in the
presence of TNF-a.
Immunoprecipitation of the 100 kD VCAM-1 protein on TEC
We also performed immunoprecipitation of VCAM-1 on
unstimulated and stimulated TEC cells (Ci). A -100 kD protein
corresponding in size to murine VCAM-l can be immunopre-
cipitated with MAb M/K-2.7 in stimulated Cl cells (Fig. 6). Due
Fig. 4. Flow cytometric analysis of TEC (CI) for VCAM-1 expression.
Control ( ) represents unstimulated cells incubated with irrelevant
MAb BIE5. Unstimulated cells ( ) or cells which were maximally
stimulated with TNF-a (100 ng/ml) plus INF-y (.; 500 U/mI) for 18
hours were stained with MAb M/K-2.7. Constitutive VCAM-1 expres-
sion is evident, and up-regulation can be detected in response to
cytokines, as indicated by a shift of the fluorescence intensity to the
right. Figure is representative of 3 similar experiments.
to the sensitivity of the method and the lower expression in
unstimulated cell, the 100 kD band was not visible in unstimu-
lated cells.
VCAM-l transcripts are upreguated by cytokines in TEC
We also studied mRNA expression of VCAM- I by TEC using
Northern blot analysis. As can be seen in Figure 7, low
steady-state mRNA levels for VCAM-1 (—3 kB) are detected in
unstimulated Cl cells. Upon stimulation with TNF-co, transcript
levels increase significantly after 30 to 60 minutes. VCAM-l
mRNA levels increase further, and reach a maximum at six
hours. Figure 7 also shows that a second mRNA species (—2
kB) appears in Cl cells upon stimulation with TNF-a. Figure 8
demonstrates that IL-i, and to a lesser extent IFN-y also
upregulate VCAM-l mRNA in Ci cells. The —2 kB transcript
also appears after stimulation with IL-l and IFN-y.
VCAM-1/VLA-4 dependent cell adherence to TEC
We have previously shown that ICAM-l/LFA-1 interactions
play an important role in the adherence of immune cells to TEC
(30]. To determine whether VCAM-l also plays a role in cell
adhesion, we investigated the blocking effect of anti-VCAM-l
and anti-VLA-4 MAb on the adherence of immune cells to
TEC. TEC (Cl) were stimulated with TNF-a IFN-yto induce
adhesion molecules. Murine T cell and macrophage cell lines
which express VLA-4 were then used in cell adherence assays.
Table 2 demonstrates that 3A9 T cells express only a low
amount of VLA-4, whereas another T cell line (C 10) and
monocytic P388D1 and IC-21 express VLA-4 more abundantly.
Table 3 shows the results of four representative cell adher-
ence assays. Stimulation of Cl with TNF-a induces a 2 to
2.5-fold increase in the adherence for 3A9, ClO, P388D1 and
IC-2l cells. A further increase in the adherence is detected
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Fig. 6. Immunoprecipitation of VCAM-1 from TEC (Cl) lysates, using
MAli MIK-2.7. Control (unstimulated) cells or maximally stimulated
cells [TNF-a (100 ng/ml) plus IFN-y (500 U/mI) for 18 hr] were
biotinylated, lysed, and immunoprecipitated. After SDS-PAGE (7.5%),
proteins were blotted onto nitrocellulose. A single 100 kD band corre-
sponding in size to muVCAM-l is detected in stimulated cells. Standard
protein size-markers are indicated on the left.
detected (Exp. 3), representing Fcy receptor-mediated adher-
ence to antibody-coated TEC. Unkeless has shown that the
adherence of antibody-coated cells (RBC) to macrophages can
be blocked with the Fcy receptor MAb 2.4G2 [17]. When this
anti-Fcy receptor MAb 2.4G2 is used in combination with
M/K-2.7, a significant inhibition of the adherence of P388D1
cells can be demonstrated, which is comparable to the inhibi-
tion seen with MAb R1-2 (Table 3, Exp. 4).
VCAM-JIVLA-4 and ICAM-1/LFA-l dependent adherence to
kidney sections
Fig. 5. Dose-response (A) and time-course (B) of VCAM-l expression
by TEC (Cl) in response to TNF-a, assayed in a cell ELISA. Cells were
stimulated for 18 hours in A, and with 100 ng/ml TNF-a in B. Results
are expressed as increase in OD at 490 nm above background (mean
SE; N = 3).
when TEC are stimulated with TNF-a plus IFN-y. The adher-
ence of 3A9 to cytokine-stimulated TEC is not inhibited with
anti-VCAM-1 MAb M/K-2.7 and anti-VLA-4 MAb Rl-2 (Exp.
1), but is inhibited with anti-ICAM-1 MAb (not shown). Exper-
iment 2 shows that the adherence of VLA-4 positive ClOT cells
to cytokine-stimulated TEC is weakly inhibited with MAb
M/K-2.7 and R1-2 (14 3% and 21 4%; P < 0.01). The
adherence of these cells is inhibited to a greater extent with
MAb YN1/1.7.4 (anti-ICAM-l; 48 5%) and M17/4.2 (anti-
LFA-1c; 78 6%). This suggests that ClO cells predominantly
adhere to TEC by using the ICAM- l/LFA- 1 adhesion pair.
Using the monocytic cell lines P388D1 and IC-2l, a more
significant inhibition is detected with MAb Rl-2, both to un-
stimulated and stimulated TEC (49 1% adherence inhibition
to stimulated TEC for P388D1, 40% 4% for IC-2l; P <0.01).
However, when Cl cells are incubated with MAb M/K-2.7, a
paradoxical increase in the adherence for P388D1 and IC-21 is
Table 4 shows that kidney sections from nephritic and
proteinuric MRL/lpr mice display a significant increase in the
adherence for ClO T cells, IC-2l macrophages, and also for
MRL//pr lymph node cells when compared with normal C3H/
FeJ and congenic MRL/++ kidneys. Adherent cells were
mainly localized at the basolateral side of tubules, and on
endothelium of large vessels. We then performed MAb inhibi-
tion studies to determine whether this increased state of adhe-
siveness is mediated by VCAM-l or ICAM-l. Figure 9A shows
that the increased adherence of ClO cells to MRLIIpr kidney
sections can be effectively blocked with anti-ICAM-l MAb, but
not with anti-VCAM-l MAb. IC-2l macrophage adherence can
be inhibited by both anti-LFA-l and anti-VLA-4 MAb (Fig.
9B). Finally, the increased adherence of MRL/lpr lymph node
cells to nephritic MRL/lpr kidney sections is blocked by both
M/K-2.7 (anti-VCAM-1) and YN1/1.7.4 (anti-ICAM-1) MAb
(Fig. 9C).
Discussion
In previous work we have shown that the adhesion molecule
ICAM- 1 is upregulated in the kidney of autoimmune mice with
renal disease [26], presumably secondary to the increased
production of the cytokines TNF-a and IL- 1 in these nephritic
kidneys [27, 31, 321. We speculated that upregulated ICAM- 1
could serve as a renal adhesion molecule by binding T cells to
MHC class II positive target cells, thereby promoting antigen
recognition and autoimmune renal injury [25, 26]. Here we
demonstrate that another adhesion molecule, VCAM-l, is also
significantly upregulated in vivo in autoimmune nephritic mice,
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Fig. 7. Northern blot analysis of total RNA
extracted from TEC (Cl). Cells were
maximally stimulated for 30 mm, 1 hr, 2 hr, 4
hr, or 6 hr with TNF-a (100 ng/ml). Blots
were hybridized with muVCAM-l (A), and
rehybridized with /3-actin eDNA (B).
Exposure time for VCAM-l was 5 days.
Steady-state VCAM-1 mRNA levels at 3.0 kB
are detected in unstimulated cells. Increased
3.0 kB mRNA levels are apparent after 30 to
60 minutes. An additional 2.0 kB transcript
appears after 0.5 to 1 hr of stimulation.
Cell type Delta OD/l08 cells
3A9 0.25 0.25
dO 5.38 0.14
P388D1 3.77 1.10
LC-21 5.77 1.53
Cells were stained with anti-VLA-4c8 MAb Rl-2 (20 .tg/ml) in a cell
ELISA. Results are expressed as increase in OD per 108 cells above
background at 490 nm (mean SE of triplicate determinations).
Fig. 8. Northern blot analysis of total RNA extracted from TEC (Cl)
which were stimulated for 6 hours with IL-I (50 ng/mi) or IFN--y (500
U/mi). Steady-state VCAM-1 transcripts at 3.0 kB are evident in
unstimulated cells (A). IL-I and IFN-y up-regulate the 3.0 kB mRNA,
and induce also a 2.0 kB transcript. Blot was also rehybridized with
/3-actin (B). Blot was exposed 5 days for VCAM-1.
and that both ICAM-! and VCAM-l function as renal adhesion
molecules for leukocytes.
In the MRL//pr kidney, VCAM-l expression is not only
increased in endothelium, but particularly in renal cortical
tubules and glomeruli. The pattern of VCAM-l expression in
MRL/lpr kidney is notably different from the previously re-
ported ICAM-l expression [26]. The tubular expression of
VCAM- 1 is more focal, localized in tubules which are adjacent
diffuse. The local release of cytokines by infiltrating mononu-
clear cells might be responsible for the focal upregulation of
VCAM- 1, thereby enabling immune cells which express VLA-4
to interact with the tubules and to cause tubular damage.
Northern analysis of kidney RNA reveals that VCAM- 1
mRNA is upregulated in autoimmune MRL//pr, correlating with
the enhanced expression seen by immunoperoxidase staining.
Two additional smaller transcripts are present in autoimmune
mice, but not in normal mice, The presence of smaller tran-
scripts in other tissues and cells has been confirmed by others
[12, 181. Due to the lower level of VCAM-l expression in
normal mice, the smaller transcripts may not be detected in the
latter. The smaller mRNA are likely caused by alternative
splicing and suggest that autoimmune MRL/lpr might express
other forms of VCAM- 1. For human VCAM- 1, it is known that
alternative splicing occurs, and that at least two VCAM-l
transcripts exist, differing by 276 bp [33—37]. In the rabbit, two
forms of VCAM-1 proteins with identical NH2-terminal amino
acid sequence have been described [38]. Further studies should
elucidate the structure, expression and functional role of alter-
nate forms of the VCAM- 1 molecule and determine its signifi-
cance in the pathogenesis of the autoimmune process in MRL/
to mononuclear infiltrates, whereas ICAM-l expression is more lpr mice.
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Table 3. Adherence of macrophage and T cell Iines to tubular epithelial cells
Total cpm
Cell line TNF-a IFN-y Antibody (mean SE)
Exneriment #1
3A9 —
—
—
100 ng/ml
100 nglml
100 nglml
100 nglml
—
—
—
—
—
—
—
—
MIK-2.7
Rl-2
—
M/K-2.7
Rl-2
BIES
6039±323
5372 566
4114 179
14099 558
14335 156
14949 349
13992 871
Experiment #2
ClO —
10 ng/ml
10 ng/ml
10 ng/ml
10 ng/ml
10 ng/ml
10 ng/ml
10 ng/ml
10 ng/ml
—
100 U/mI
100 U/mI
100 U/mI
100 U/mI
100 U/mI
100 U/mI
100 U/mI
—
—
—
M/K-2.7
YN1/1.7.4
M/K-2.7 + YNI/1.7.4
R1-2
M17/4.2
R1-2 + M17/4.2
1118±52
2639 84
7370 134
6341 89
3826 204
3212 130
5847 36
1591 59
1439 26
Exneriment #3
P388D1 —
—
—
100 ng/ml
100 ng/ml
100 ng/ml
100 ng/ml
—
—
—
—
—
—
—
—
M/K-2.7
R1-2
—
M/K-2.7
R1-2
B1E5
2611 348
3130 420
1451 296
5838 297
19175 824
2992 56
5239 230
IC-21 —
—
—
100 ng/ml
100 ng/ml
100 ng/mI
100 ng/ml
—
—
—
—
—
—
—
—
M/K-2.7
R1-2
—
M/K-2.7
Rl-2
B1E5
4071 379
3937 160
2338 205
10732 555
12190 180
6394 384
9946 357
Experiment #4
P388D1 —
100 ng/ml
100 ng/ml
100 nglml
100 ng/ml
100 ng/ml
—
—
—
—
—
—
—
—
M/K-2.7
Rl-2
2.4G2
M/K-2.7 + 2.4G2
747 52
1750 171
3997 323
661 87
1420 95
805 42
Tubular epithelial cells (Cl) were grown to confluence in 96-well plates, and were stimulated overnight with TNF-a IFN-y. T cells (3A9, ClO)
and macrophages (P388D1, IC-2l) labeled with 5tCr (l05/well) were added for 90 minutes to TEC in the presence or absence of the indicated MAb
(all were used as supernatants at 1:20, except for purified anti-VLA-4 MAb Rl-2 which was used at 10 j.tg/ml). Non-adherent cells were removed
by washing the wells three times with media. Results are expressed in cpm (mean SE, triplicate determinations). Total counts added to each well
were as follows: Exp. 1, 34500 (3A9); Exp. 2, 31827 (ClO); Exp. 3, 36692 (P388D1) and 27032 (IC-21); Exp. 4, 23052 (P388D1).
Table 4. Adherence of T cells and macrophages to kidney sections
Strain N
Adherent cell type
ClO IC-21 LN cells
C3H/FeJ
MRL/++
MRLIIpr
3
2
4
6.3 2.3
nd
24.2 3•9a
2.1 0.8
4.4 1.5
23.0 8.6a
3.9 1.5
5.1 1.6
13.3 l.9a
dO T cells, IC-2l macrophages, and MRL/lpr lymph node (LN) cells
(2 x 106/section) were adhered to 20 m kidney cryostat section for 20
mm. at room temperature. Adherent cells were counted in 6 high power
fields and were averaged. N indicates number of animals examined.
Data represent mean SE. nd denotes not done.
a P < 0.05 when compared with cell number adherent to C3H/FeJ and
MRL/+ + kidneys
Our in vitro data demonstrate that cytokines stimulate
VCAM-l expression in renal parenchymal cells. VCAM-1 is
dose-dependently upregulated in TEC and MC cells by TNF-a
and IL-i, suggesting that these cytokines may induce VCAM-1
in these cells in vivo. In addition, unlike in human endothelial
cells [1], IFN-y is also a stimulus for VCAM-l. In addition, a
further stimulation occurs when IFN-y and TNF-a are com-
bined. These cytokines are abundantly expressed in MRL/lpr
with lupus nephritis, and are the probable cause of enhanced
VCAM-l and ICAM-l expression in vivo. Adhering inflamma-
tory cells which produce cytokines in situ may cause local
upregulation of adhesion molecules, thereby recruiting addi-
tional inflammatory cells (positive feed-back loop). The inter-
ruption of this cycle with MAb targeting these adhesion mole-
cules might thus be a promising approach to inhibit the
pathological infiltration of inflammatory cells in murine lupus
nephritis.
The interaction of immune cells with parenchymal cells of
nonhematopoietic lineage involves multiple ligands, including
ICAM-l/LFA-i and VCAM-1/VLA-4 [reviewed in 39]. The
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VCAM-l/VLA-4 binding pair is an important cell adhesion
mechanism by which lymphocytes [1—3], monocytes [40], eo-
sinophils [41, 421, and basophils, but not neutrophils [43],
adhere to endothelium. YCAM- l/VLA-4 interactions have been
shown to occur in human rheumatoid arthritis [44] and rat
adjuvant arthritis [45]. Here we show that VCAM- 1/VLA-4 and
ICAM-l/LFA-l binding also plays a role in MRL/lpr lupus
nephritis.
Previous work has shown that renal tubular epithelial
ICAM-1 promotes adhesion of LFA-l-positive immune cells
[30, 46, 47]. Furthermore, renal tubular ICAM-1 plays a role in
antigen presentation [30] and cytotoxic injury by T cells [47].
Upregulated ICAM- 1 may thus play a role in kidney transplant
rejection [46—48] and other immune-mediated renal diseases
[49, 50]. Here we demonstrate that VCAM- 1 also promotes
adherence of immune cells to renal parenchymal cells, and that
both ICAM- 1 and VCAM- 1 cause a state of increased adher-
ence in the kidney of MRL/Ipr mice. Specifically, the adherence
of T cell lines and macrophages to TEC can be inhibited with
MAb to VCAM- 1 and VLA-4. This demonstrates that in addi-
tion to ICAM-l/LFA-1 binding, immune cells can use the
VCAM-l/VLA-4 pathway to adhere to TEC. Furthermore,
adherence assays using MRL/lpr kidney sections directly dem-
onstrate that the renal parenchyma of these nephritic mice
displays a state of increased adherence for immune cells.
Inhibition studies with MAb show that the enhanced "sticki-
ness" in these kidneys is caused by upregulated ICAM-l and
VCAM-l.
Increased adherence to MRL//pr kidney can also be demon-
strated for lymph node cells from MRL/lpr mice, suggesting
that pathogenic T cells and/or macrophages which are overpro-
duced in these mice might migrate into the kidney and adhere.
Since VCAM- l/VLA-4 and ICAM- l/LFA- 1 interactions are an
important mechanism by which inflammatory cells bind to the
renal parenchyma, we speculate that upregulation of VCAM-l
together with ICAM- 1 therefore plays an important role in the
pathogenesis of murine lupus nephritis and other immune-
mediated renal diseases.
In summary, we have shown that VCAM-1 is upregulated in
the kidney of autoimmune MRL/lpr mice with renal disease. In
nephritic mice this cell adhesion molecule is abundantly ex-
pressed in the kidney by endothelium, renal tubular epithelium
and mesangial cells. VCAM-l is upregulated in vitro in tubular
epithelial and mesangial cells by TNF-a, IL-l and IFN-y, and
5 has the ability to mediate VLA-4 dependent adhesion of mono-
nuclear leukocytes. VCAM-l, together with ICAM-1, contrib-
utes to the overall increased state of adherence for immune cells
in the kidney of autoimmune MRL/lpr mice. Thus, ICAM-l and
VCAM- 1 specifically promote the interaction of immune cells
+ . with renal parenchymal target cells in murine lupus neprhitis.N r-.
Acknowledgments
This work was supported by NIH grant DK-39258 and the Nephrol-
Fig. 9. Adherence of ClO T cells (A), IC-21 macrophages (B) and ogy Research and Training Center. Part of this work was presented at
MRL/lpr lymph node cells (C) to 4-month-old nephritic MRL/lpr kidney the 1991 annual meeting of the American Society of Nephrology in
sections. Inhibitory MAb M/K-2.7 (anti-VCAM-l), YN 1/1.7.4 (anti- Baltimore, MD, and has been published in abstract form (J Am Soc
ICAM-1), M17/4.2 (anti-LFA- I a) and R1-2 (anti-VLA-4a) were added Nephrol 2(3):568A, 1991). We thank Dr. David G. Warnock for his
together with 2 x 106 cells/section. Adherent cells were counted in 6 support and encouragement. Dr. Mark Benfleld provided us with
high power fields and averaged. Data represent mean cell number per mesangial cells. We also thank Teresa A. Jenkins and Padmini Sekar for
high power field SE from three representative experiments, assistance in the laboratory, and Keith Berry from the Multipurpose
151T
10
N
cJ00
Wuthrich: VCAM-1 in marine lupus nephritis 913
Arthritis Center for performing the FACS analyses. We are grateful for
the following materials used in this study: anti-VCAM-1 antibody from
Dr. P.W. Kincade; anti- VLA-4 antibody from Dr. I. Weissman; murine
VCAM-i eDNA from Dr. R. Lobb; rmulL-l from Hoffman-La Roche;
rmuTNF-a and rmuIFN-y from Genentech Inc.; rmulL-4 from Sterling
Drug Inc.; rmulL-6 from Genetics Institute. The authors express their
gratitude to Sandoz Pharmaceuticals Corporation, East Hannover,
New Jersey, U.S.A. for the grant to publish figure 1 in color.
Reprint requests to Rudolf P. Wuthrich, M.D., Division of Nephrol-
ogy, University of Alabama at Birmingham, LHR 668B, UAB Station,
Birmingham, Alabama 35294, USA.
References
1. Osaoi L, HESSION C, TIZARD R, VASSALLO C, LUHOWSKY 5,
CHI-Rosso G, LOBB R: Direct expression cloning of vascular cell
adhesion molecule-i, a cytokine-induced endothelial protein that
binds to lymphocytes. Cell 59:1203—1211, 1989
2. RIcE GE, MUNRO JM, BEVILACQUA MP: Inducible cell adhesion
molecule 110 (INCAM-1 10) is an endothelial receptor for lympho-
cytes. A CD1 1/CD18 independent adhesion mechanism. J Exp Med
171:1369—1374, 1990
3. CARLOS TM, SCHWARTZ BR, KOVACH NL, YEE E, Rosso M,
OSBORN L, NEWMAN B, LOBB R, HARLAN JM: Vascular cell
adhesion molecule-i mediates lymphocyte adherence to cytokine-
activated cultured human endothelial cells. Blood 76:965—970, 1990
4. ELICES MJ, OSBORN L, TAKADA Y, HEMLER ME, LOBB R:
VCAM-1 on activated endothelium interacts with the leukocyte
integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding
site. Cell 60:577—584, 1990
5. GRABER N, GOPAL TV, WILSON D, BEALL LD, POLTE T, NEWMAN
W: T cells bind to cytokine-activated endothelial cells via a novel,
inducible sialoglycoprotein and endothelial leukocyte adhesion
molecule-i. J Immunol 145:819—830, 1990
6. RICE GE, MUNRO JM, CORLESS C, BEVILACQUA MP: Vascular and
nonvascular expression of INCAM-l 10. A target for mononuclear
leukocyte adhesion in normal and inflamed human tissues. Am J
Pathol 138:385—393, 1991
7. SHIMIZU Y, NEWMAN W, GOPAL TV, HORGAN KJ, GRABER N,
BEALL LD, VAN SEVENTER GA, SHAW 5: Four molecular path-
ways of T cell adhesion to endothelial cells: Roles of LFA-1,
VCAM-1, and ELAM- 1 and changes in pathway hierarchy under
different activation conditions. J Cell Biol 113:1203—1212, 1991
8, OPPENHEIMER-MARKS N, DAVIS LS, BOGUE DT, RAMBERG J,
LIPSKY PE: Differential utilization of ICAM-l and VCAM-l during
the adhesion and transendothelial migration of human T lympho-
cytes. Jlmmunol 147:2913—2921, 1991
9. MIYAKE K, WEISSMAN IL, GREENBERGER JS, KINCADE PW:
Evidence for a role of the integrin VLA-4 in lympho-hemopoiesis.
J Exp Med 173:599—607, 1991
10. FREEDMAN AS, MUNRO JM, RICE GE, BEVILACQUA MP, M0RIM-
OTO C, MCINTYRE BW, RHYNHART K, POBER JS, NADLER LM:
Adhesion of human B cells to germinal centers in vitro involves
VLA-4 and INCAM-llO. Science 249:1030—1037, 1990
11. KOCH AE, BURROWS JC, HAINES GK, CARLOS TM, HALAN JM,
LEIB0vICH SJ: Immunolocalization of endothelial and leukocyte
adhesion molecules in human rheumatoid and osteoarthritic syno-
vial tissues. Lab Invest 64:313—320, 1991
12. MIYAKE K, MEDINA K, ISHIHARA K, KIMOTO M, AUERBACH R,
KINCADE PW: A VCAM-like adhesion molecule on murine bone
marrow stromal cells mediates binding of lymphocyte precursors in
culture. J Cell Biol 114:557—565, 1991
13. HOLZMANN B, MCINTYRE BW, WEISSMAN IL: Identification of a
murine Peyer's patch-specific lymphocyte homing receptor as an
integrin molecule with an a chain homologous to human VLA-4a.
Cell 56:37—46, 1989
14. WERB Z, TREMBLE PM, BEHRENDTSEN 0, CROWLEY E, DAMSKY
CH: Signal transduction through the fibronectin receptor induces
collagenase and stromelysin gene expression. J Cell Biol 109:877—
889, 1989
15. TAKE! F: Inhibition of mixed lymphocyte response by a rat mono-
clonal antibody to a novel murine lymphocyte activation antigen
(MALA-2). J Immunol 134:1403—1407, 1985
16. SANCHEZ-MADRID F, DAVIGNON D, MARTZ E, SPRINGER TA:
Antigens involved in mouse cytolytic T-lymphocyte (CTL)-medi-
ated killing: Functional screening and topographic relationship.
Cell lmmunol 73:1—11, 1982
17. UNKELESS JC: Characterization of a monoclonal antibody directed
against mouse macrophage and lymphocyte Fc receptors. J Exp
Med 150:580—596, 1979
18. HESSION C, Mov P, TIZARD R, CHISHOLM P. WILLIAMS C, WYSK
M, BURKLY L, MIYAKE K, KINCADE PW, LOBB R: Cloning of
murine and rat vascular cell adhesion molecule-i. Biochem Biophys
Res Commun 183:163—169, 1992
19. WUTHRICH RP, GLIMCHER LH, YUI MA, JEVNIKAR AM, DUMAS
SE, KELLEY VE: MHC class II, antigen presentation and tumor
necrosis factor in renal tubular epithelial cells. Kidney mt 37:783—
792, 1990
20. HARPER PA, ROBINSON JM, HOOVER RL, WRIGHT TC, KAR-
NOVSKY MJ: Improved methods for culturing rat glomerular cells.
Kidney mt 26:91—96, 1984
21. BRENNAN DC, JEVNIKAR AM, TAKE! F, RUBIN KELLEY VE:
Mesangial cell accessory functions: Mediation by intercellular
adhesion molecule-I. Kidney mt 38:1039—1046, 1990
22. HAVERTY TP, KELLEY CJ, HINES WH, AMENTA PS, WATANABE
M, HARPER RA, KEFALIDES NA, NEILSON EG: Characterization of
a renal tubular epithelial cell line which secretes the autologous
target antigen of autoimmune experimental interstitial nephritis. J
Cell Biol 107:1359—1368, 1988
23. ALLEN PM, UNANUE ER: Differential requirement for antigen
processing by macrophages for lysozyme-specific T cell hybrid-
omas. J Immunol 132:1077—1079, 1984
24. NABAVI N, GHOGAWALA Z, MYER A, GRIFFITH IJ, WADE WF,
CHEN ZZ, MCKEAN DJ, GLIMCHER LH: Antigen presentation
abrogated in cells expressing truncated Ia molecules. J Immunol
142:1444—1447, 1989
25. WUTHRICH RP, YuI MA, MAZOUJIAN G, NABAVI N, GLIMCHER
LH, KELLEY VE: Enhanced MHC class II expression in renal
proximal tubules precedes loss of renal function in MRL/lpr mice
with lupus nephritis. Am J Pathol 134:45—51, 1989
26. WUTHRICH RP, JEVNIKAR AM, TAKE! F, GLIMCHER LH, KELLEY
VE: Intercellular adhesion molecule-l (ICAM-i) expression is
upregulated in autoimmune murine lupus nephritis. Am J Pathol
136:441—450, 1990
27. BOSWELL JM, Yu! MA, ENDRES S, BURT DW, KELLEY VE: Novel
and enhanced IL-I gene expression in autoimmune mice with
lupus. J Immunol 141:118—124, 1988
28. CHOMCZYNSKI P, SACCHI N: Single-step method of RNA isolation
by acid guanidium thiocyanate-phenol-chloroform extraction. Anal
Biochem 162:156—159, 1987
29. FEINBERG AP, VOGELSTEIN B: A technique for radiolabeling DNA
restriction endonuclease fragments to high specific activity. Anal
Biochem 132:6—13, 1983
30. JEVNIKAR AM, WUTHRICH RP, TAKEI F, Xu HW, BRENNAN DC,
GLIMCHER LH, RUBIN KELLEY VE: Differing regulation and func-
tion of ICAM-l and class II antigens on renal tubular cells. Kidney
Int 38:417—425, 1990
31. BOSWELL JM, YuI MA, BURT DW, KELLEY VE: Increased tumor
necrosis factor and IL-113 gene expression in the kidneys of mice
with lupus nephritis. J Immunol 141:3050—3054, 1988
32. BRENNAN DC, YUI MA, WUTHRICH RP, KELLEY VE: Tumor
necrosis factor and IL-i in New Zealand Black/White mice. J
Immunol 143:3470—3475, 1989
33. POLTE T, NEWMAN W, GOPAL TV: Full length vascular cell
adhesion molecule-i (VCAM-i). Nucleic Acids Res 18:5901, 1990
34. HESSION C, TIZARD R, VASSALLO C, SCHIFFER SB, GOFF D, Mov
P, CHI-Rosso G, LUHOWSKY! 5, LOBB R, 0sao L: Cloning of an
alternate form of vascular cell adhesion molecule-I (VCAMI). J
Biol Chem 266:6682—6685, 1991
35. POLTE T, NEWMAN W, RAGHUNATHAN G, GOPAL TV: Structural
914 Wuthrich: VCAM-1 in murine lupus nephritis
and functional studies of full length vascular cell adhesion mole-
cule-i (VCAM-l): Internal duplication and homology to several
adhesion proteins. DNA Cell Biol 10:349—357, 1991
36. CYBULSKY MI, FRIES JWU, WILLIAMS AJ, SULTAN P, DAvIs VM,
GIMERONE MA, COLLINS T : Alternative splicing of human
VCAM-1 in activated vascular endothelium. Am J Pathol 138:815—
820, 1991
37. CYBULSKY MI, FRIES JWU, WILLIAMS AJ, SULTAN P, EDDY R,
BYERS M, SHOWS T, GIMBRONE MA, COLLINS T: Gene structure,
chromosomal location, and basis for alternative mRNA splicing of
the human VCAM-i gene. Proc Nati Acad Sci USA 88:7859—7863,
1991
38, CYBULSKY MI, GIMBRONE MA: Endothelial expression of a mono-
nuclear leukocyte adhesion molecule during atherogenesis. Science
251:788—791, 1991
39. SPRINGER T: Adhesion receptors of the immune system. Nature
346:425—434, 1990
40. CARLOS T, KOVACH N, SCHWARTZ B, ROSA M, NEWMAN B,
WAYNER E, BENJAMIN C, OSBORN L, LoBE R, HARLAN J: Human
monocytes bind to two cytokine-induced adhesive ligands on
cultured human endothelial cells: Endothelial-leukocyte adhesion
molecule-l and vascular cell adhesion molecule-l. Blood 77:2266—
2271, 1991
41. DOBRINA A, MENEGAZZI R, CARLOS TM, NARD0N E, CRAMER R,
ZACCHI T, HARLAN JM, PATRIARCA P: Mechanism of eosinophil
adherence to cultured vascular endothelial cells. J C/in Invest
88:20—26, 1991
42. WELLER PF, RAND TH, GOELZ SE, CHI-Rosso G, LOBB RR:
Human eosinophil adherence to vascular endothelium mediated by
binding to vascular cell adhesion molecule-I and endothelial leuko-
cyte adhesion molecule-i. Proc Nail Acad Sci USA 88:7430—7433,
1991
43. BOCHNER BS, LUSCINSKAS FW, GIMBRONE MA, NEWMAN W,
STERBINSKY SA, DERSE-ANTHONY CP, KLUNK D, SCHLEIMER RP:
Adhesion of human basophils, eosinophils, and neutrophils to
interleukin-1 activated human vascular endothelial cells: Contribu-
tions of endothelial cell adhesion molecules. J Exp Med 173:1553—
1556, 1991
44. DINTHER-JANSSEN AC, HORST E, K0OPMAN G, NEWMAN W,
SCHEPER RJ, MEIJER CJ, PALS ST: The VLA-4/VCAM-1 pathway
is involved in lymphocyte adhesion to endothelium in rheumatoid
synovium. J Immunol 147:4207—4210, 1991
45. ISSEKUTZ TB, ISSEKUTZ AC: T lymphocyte migration to arthritic
joints and dermal inflammation in the rat: Differing migration
patterns and the involvement of VLA-4. C/in Immunol Immu-
nopathol 61:436—447, 1991
46. BISHOP GA, HALL BM: Expression of leukocyte and lymphocyte
adhesion molecules in the human kidney. Kidney mt 36:1078—1085,
1989
47. SURANYI MG, BISHOP GA, CLAYBERGER C, KRENSKY AM, LEE-
NAERTS P, AVERSA G, HALL BM: Lymphocyte adhesion molecules
in T cell-mediated lysis of human kidney cells. Kidney mt 39:3 12—
319, 1991
48. FAULL RJ, Russ GR: Tubular expression of intercellular adhesion
molecule-I during renal allograft rejection. Transplantation 48:226—
230, 1989
49. LH0TTA K, NEuMAYER HP, JOANNIDIS M, GEISSLER D, KONIG P:
Renal expression of intercellular adhesion molecule-I in different
forms of glomerulonephritis. C/in Sci 81:477-481, 1991
50. MARK0vIc-LIP0v5KI J, MULLER CA, RISLER T, BOHLE A,
MULLER GA: Mononuclear leukocytes, expression of HLA class II
antigens and intercellular adhesion molecule-i in focal segmental
glomerulosclerosis. Nephron 59:286—293, 1991
